Generate Biomedicines filed for an initial public offering to fund global Phase III programs for GB‑0895, an AI‑designed anti‑TSLP antibody now entering pivotal trials in severe asthma. The company said proceeds will complete two Phase III SOLAIRIA trials and support an ongoing Phase Ib COPD study and further development. GB‑0895 is designed for infrequent dosing — the company highlighted potential six‑month subcutaneous administration — and Generate emphasized its partnerships with Amgen and Novartis and prior private fundraising as validation of its programmable‑biology platform.